D&D Pharmatech
| Market cap | ₩2.2T |
| PE ratio | – |
| Forward PE | – |
| PB ratio | 16.18 |
| EPS | −₩495 |
| Dividend (yield) | – |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 1,135,162 |
| Trading value | ₩52.4B |
| Day’s range | ₩42,850 – ₩48,350 |
| 52-week range | ₩39,990 – ₩116,600 |
| Foreign ownership KR | 10.68% |
| Foreign net buy (Oct 2) KR | −83,045 sh |
| Book value / share | ₩2,939 |
| Founded | 2014 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩43,000 | −83,045 | −16,914 | +102,012 | 10.68% |
| Oct 1 | ₩45,250 | +20,238 | +82,621 | −106,552 | 10.86% |
| Sep 30 | ₩41,850 | +41,032 | −21,309 | −21,298 | 10.84% |
| Sep 29 | ₩41,950 | +64,484 | −35,269 | −23,462 | 10.60% |
| Sep 28 | ₩43,200 | −122,870 | +10,001 | +85,951 | 10.48% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩18.7B | ₩11.4B | ₩4.3B | – |
| Operating income | −₩13.5B | −₩25.0B | −₩34.0B | – |
| Net income | ₩3.4B | −₩29.5B | −₩24.0B | – |
| Operating margin | −72.21% | −218.74% | −790.97% | – |
| Return on equity | 14.03% | −49.03% | −31.49% | – |
| Debt-to-equity | 43.44% | 40.15% | 23.50% | – |
| EPS | ₩110 | −₩706 | −₩547 | – |
| Dividend per share | – | – | – | – |
Peers
| Alteogen 196170 | ₩260,000 | +0.19% |
| Peptron 087010 | ₩130,600 | +0.85% |
| ABL Bio 298380 | ₩52,500 | +2.14% |
| Hugel 145020 | ₩181,500 | +0.78% |
| Aimed Bio 0009K0 | ₩25,800 | +4.03% |
| Naturecell 007390 | ₩24,750 | 0.00% |
About
D&D Pharmatech researches and develops peptide-based drugs such as GLP-1 therapies, with a pipeline that includes oral obesity treatments and drugs for MASH, Parkinson's disease and Alzheimer's disease. It runs global clinical development through a US subsidiary and uses PEGylation technology and its ORALINK platform to discover and improve GLP-1 peptide drugs. Founded in 2014, it listed on the KOSDAQ in 2024 as a technology growth company.
D&D Pharmatech Inc. is listed on the KOSDAQ market of the Korea Exchange under the ticker 347850. Industry: Research & development.
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 6, 2026; investor flows as of Oct 2, 2026. Delayed data, not investment advice.